These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35549626)

  • 21. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
    Cazzola M; Della Porta MG; Malcovati L
    Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
    Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myelodysplastic syndromes and the role of iron overload.
    Harvey RD
    Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital.
    Bauduer F; Recanzone H
    Transfus Clin Biol; 2020 Aug; 27(3):128-132. PubMed ID: 32561328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
    Buckstein R; Chodirker L; Yee KWL; Geddes M; Leitch HA; Christou G; Banerji V; Leber B; Khalaf D; St-Hilaire E; Finn N; Nevill T; Keating MM; Storring J; Parmentier A; Thambipillai A; Tang D; Westcott C; Cameron C; Spin P
    Leuk Lymphoma; 2023 Mar; 64(3):651-661. PubMed ID: 36606533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCE.
    Buckstein R; Callum J; Prica A; Bowen D; Wells RA; Leber B; Heddle N; Chodirker L; Cheung M; Mozessohn L; Yee K; Gallagher J; Parmentier A; Jamula E; Zhang L; Mamedov A; Stanworth SJ; Lin Y
    Transfusion; 2024 Feb; 64(2):223-235. PubMed ID: 38323704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and treatment of anemia and secondary iron overload in patients with a myelodysplastic syndrome: Real-world data from a multicenter cohort study.
    de Roij van Zuijdewijn CLM; Westerweel PE; Schipperus MR; Pruijt JFM; van de Loosdrecht AA; Beeker A
    Transfus Clin Biol; 2023 Aug; 30(3):314-318. PubMed ID: 37061177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes.
    Mo A; Wood E; Shortt J; Charlton A; Evers D; Hoeks M; Pritchard E; Daly J; Hodgson C; Opat S; Bowen D; Reynolds J; Thi Phung Thao L; Stanworth SJ; McQuilten Z
    Transfusion; 2024 Feb; 64(2):236-247. PubMed ID: 38214417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.
    Greenberg PL; Rigsby CK; Stone RM; Deeg HJ; Gore SD; Millenson MM; Nimer SD; O'Donnell MR; Shami PJ; Kumar R
    J Natl Compr Canc Netw; 2009 Dec; 7 Suppl 9():S1-16. PubMed ID: 20064286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM; Komrokji RS
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Iron overload and myelodysplastic syndromes].
    Rose C; Cambier N; Mahieu M; Ernst O; Fenaux P
    Transfus Clin Biol; 2001 Oct; 8(5):422-32. PubMed ID: 11729396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.
    Steensma DP
    Curr Hematol Malig Rep; 2011 Jun; 6(2):136-44. PubMed ID: 21373838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C; Clissa C; Stanzani M
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S; Santini V; Musallam K; Taher A
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
    Balducci L
    Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron overload in myelodysplastic syndromes (MDS).
    Gattermann N
    Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
    Wong SA; Leitch HA
    Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron chelation therapy in myelodysplastic syndromes.
    Fausel CA
    Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S10-4; quiz S16. PubMed ID: 20332500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.